Previous 10 | Next 10 |
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4...
Announcing topline data from a Phase 2a clinical trial involving patients with hearing loss, the clinical-stage biopharma company, Otonomy (NASDAQ:OTIC), said on Wednesday that a single injection of OTO-413 led to a “clinically meaningful treatment benefit versus placebo” across...
Otonomy (NASDAQ:OTIC) on Wednesday announced what it deemed to be positive results from its phase 2a trial of its formulation OTO-413 in patients with hearing loss. OTIC stock was volatile in premarket trading, gaining and losing as much as 17.5% each to $2.55 and $1.79, respectively. Shares ...
Clarus Therapeutics (CRXT) +18%. AlloVir (ALVR) +18% on FDA regenerative medicine tag for posoleucel to prevent 6 viruses in cell transplant patients. Westwater Resources (WWR) +15% and Alabama Graphite Products break ground on Kellyton processing plant. IceCure Medical (...
Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trial Enrollment in higher dose cohorts is on...
Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indication...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
The following slide deck was published by Otonomy, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Otonomy, Inc. 2021 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. Otonomy (NASDAQ: OTIC) Q4 2021 Earnings Call Feb 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Otonomy (OTIC) Q4 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...